QIAGEN N.V. [NYSE: QGEN] disclosed that it has added the number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has established new standards by using so-called nanoplates to process samples in two hours rather than the five hours mandated by other systems.
QIAGEN has started a partnership that extends the QIAcuity ecosystem. One partnership with Atila BioSystems to offer non-invasive prenatal testing (NIPT) solutions to QIAGEN’s dPCR franchise. NIPT needs only a blood sample from the mother and substitutes more invasive testing methods such as amniocentesis that can threaten the fetus and mother’s life.
Furthermore, another partnership of the company is the inking of co-exclusive licensing and co-marketing agreement with German life-sciences start-up Actome GmbH extends QIAcuity’s reach beyond genomics into proteomics, allowing the quantification of proteins as well as the examines of connections between different proteins and between proteins and target genes.
In addition, QIAcuity helps to distribute a sample across thousands of microscopic nanoplate partitions and detects the response in each one at the same time. This allows it to detect even the tiniest signals from DNA and RNA when testing for viruses, bacteria, or other diseases, such as uncommon cancer mutations. QIAcuity’s precision has already made it a valuable tool for testing wastewater for SARS-CoV-2.
Moreover, Actome and QIAGEN have entered into a co-marketing agreement that grants QIAGEN a co-exclusive license for digital PCR applications to use Actome’s trademarked Protein-Interaction-Coupling (PICO)-Technology on QIAcuity as an ultrasensitive instrument to assess slightest amounts of proteins and the interplay between proteins as well as between proteins and genes.